Glenmark Pharmaceuticals Ltd

Desk›Healthcare› Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd

BSE 532296 · NSE GLENMARK · ISIN INE935A01035 · Group A · Active

Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

₹2,456.00

+0.66%

BSE close, 28 August 2026

Market cap

₹69,314.38 cr

28.2 cr shares · Mid cap

Free float

₹36,864.02 cr

as published

P/E · P/B

338.8× · 2.89×

EPS ₹7.25 · BV ₹849.83

FY25-26 rev / PAT

8,440.10 / -200.80

₹ cr, as filed

Filings, window

12 selected · 43%

Regime

Reg 30

Sch. III Part A

Price 52-week, BSE

Against 52-week high	-1.1%
Against 52-week low	+36.9%
Day change	+0.66%
Size band	Mid cap
Index membership	NIFTY 500

Valuation as published by BSE

Earnings per share	₹7.25
Price / earnings	338.76×
Price / book	2.89×
Book value — derived, price ÷ P/B	₹849.83
Return on equity	0.85%
Operating margin	39.08%
Net margin	30.21%

Consistency check

P/B ÷ P/E, which must equal ROE: 0.85%
ROE as published: 0.85%

Results ₹ crore, as filed

Jun-26 · Q

Mar-26 · Q

FY25-26

RevenueNet profit one scale across all three periods, ₹ crore

Period	Revenue ₹cr	Net profit ₹cr	EPS ₹	OPM	NPM
Jun-26 · Q	2,434.99	735.64	26.07	39.08%	30.21%
Mar-26 · Q	2,146.58	-73.90	-2.62	-1.37%	-3.44%
FY25-26	8,440.10	-200.80	-7.12	0.58%	-2.38%

Quarter on quarter

Revenue, quarter on quarter: +13.4%
Net profit, quarter on quarter: +1,095.5%
Operating margin, quarter on quarter: +4,045 bps

Disclosure profile 28 filings in the window

Shaded is the middle half of the sector, 12 to 25 filings. Measured against the 300 Healthcare companies that filed at all in this window — companies with no filings are excluded, so this is a percentile against filers rather than against the sector.

Tag	Filings
Selected
Press Release	8
Board Outcome	1
Concall Transcript	1
Credit Rating	1
Investor Presentation	1
Selected sub-total	12
Procedural
Analyst / Investor Meet	4
AGM / EGM	3
General	3
Annual Report	1
BRSR	1
ESOP Allotment	1
Newspaper Publication	1
Record Date	1
Trading Window	1
Procedural sub-total	16
Total	28

Disclosure regime

LODR Reg 30

Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.

Sources Price, day change, 52-week range — bse.quote, bse.quoteWeeklyHL, 28 August 2026 close. Market cap and free float — bse.getScripTradingStats. P/E, P/B, EPS, ROE, margins — bse.equityMetaInfo. Quarterly and annual results — bse.resultsSnapshot, standalone, as filed. Four-tier classification — data/reference/companies.csv. Filing counts and tags — the build aggregate for this window. Notes Book value is derived as price ÷ P/B; BSE does not publish it directly. Share count is derived as market cap ÷ price. Figures move between captures and between vendors, and the two are not an error in either: companies.csv carries the market cap from an earlier sweep than the snapshot above. EPS appears twice with different meanings — the figure beside P/E is the trailing one from equityMetaInfo, while the EPS in the results table is the per-period figure as filed.

Filing rhythm · 93 trading days

28 filings · 12 selected · busiest 2026-07-31

Filing rhythm · the twelve most recent

2026-08-132026-10-06

SelectedProcedural

Filings

28 in the window · 11 earlier on record

6 October 2026 · 08:39 IST

Press Release

Press Release / Media Release

Glenmark Therapeutics Inc. USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC)

Company Update / Press Release / Media Release View filing →
28 September 2026 · 18:09 IST

Trading Window

Closure of Trading Window

Intimation for closure of trading window for second quarter of FY 2026-27

Insider Trading / SAST / Closure of Trading Window View filing →
23 September 2026 · 08:46 IST

Press Release

Press Release / Media Release

Glenmark Pharmaceuticals receives Establishment Inspection Report (EIS) from U.S. FDA for its Goa facility with VAI classification

Company Update / Press Release / Media Release View filing →
21 September 2026 · 14:58 IST

Analyst / Investor Meet

Analyst / Investor Meet - Intimation

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Schedule of Analyst/ Institutional Investor Meetings

Company Update / Analyst / Investor Meet View filing →
11 September 2026 · 18:57 IST

AGM / EGM

Shareholder Meeting / Postal Ballot-Scrutinizer's Report

Report of Scrutinizer is enclosed

AGM/EGM / AGM View filing →
11 September 2026 · 18:54 IST

AGM / EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

Proceedings of the 48th AGM of the Company is enclosed

AGM/EGM / AGM View filing →
11 September 2026 · 08:50 IST

Press Release

Press Release / Media Release

Glenmark expands Global Respiratory Innovation Footprint with RYALTRIS launch in Brazil

Company Update / Press Release / Media Release View filing →
11 September 2026 · 08:45 IST

Credit Rating

Credit Rating

Please find enclosed rating rationale issued by India Ratings and Research

Company Update / Credit Rating View filing →
21 August 2026 · 08:52 IST

Press Release

Press Release / Media Release

Glenmark Pharmaceuticals Inc., USA launches Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy ....

Company Update / Press Release / Media Release View filing →
20 August 2026 · 08:53 IST

Press Release

Press Release / Media Release

Glenmark Pharmaceuticals receives U.S. FDA approval for Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray

Company Update / Press Release / Media Release View filing →
13 August 2026 · 21:36 IST

General

Letter To Shareholders Whose Email Address Are Not Registered Providing The Web Link Of Annual Report

Letter to Shareholders whose email address are not registered providing the web link of Annual Report

Company Update / General View filing →
13 August 2026 · 20:25 IST

BRSR

Business Responsibility and Sustainability Reporting (BRSR)

Please find attached Business Responsibility and Sustainability Reporting for Financial Year 2025-26

Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →
13 August 2026 · 20:11 IST

Annual Report

Reg. 34 (1) Annual Report.

Please find attached Notice convening the 48th Annual General Meeting and the Integrated Annual Report including BRSR for the Financial Year 2025-26.

Others / Reg. 34 (1) Annual Report View filing →
13 August 2026 · 19:55 IST

AGM / EGM

Notice Of The 48Th Annual General Meeting For The Financial Year 2025-26

Please find attached Notice of 48th Annual General Meeting for the Financial Year 2025-26

AGM/EGM / AGM View filing →
11 August 2026 · 22:50 IST

General

Settlement Agreement - Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015

Settlement Agreement - Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

Company Update / General View filing →
10 August 2026 · 15:08 IST

ESOP Allotment

Allotment of ESOP / ESPS

Intimation of Allotment of shares under the Employee Stock Option Plan 2016

Company Update / Allotment of ESOP / ESPS View filing →
7 August 2026 · 14:52 IST

Analyst / Investor Meet

Analyst / Investor Meet - Intimation

Intimation of Schedule of Analyst / Institutional Investor Meetings

Company Update / Analyst / Investor Meet View filing →
7 August 2026 · 13:23 IST

Newspaper Publication

Newspaper Publication

Newspaper Advertisement regarding the 48th Annual General Meeting ("the AGM") to held through Video Conferencing ("VC")/ Other Audio-Visual Means ("OAVM")

Company Update / Newspaper Publication View filing →
5 August 2026 · 16:08 IST

Concall Transcript

Earnings Call Transcript

Transcript of the Earnings Call

Company Update / Earnings Call Transcript View filing →
3 August 2026 · 16:30 IST

Analyst / Investor Meet

Analyst / Investor Meet - Outcome

Audio recording of Q1 FY 2026-27 Earnings Call held on August 03, 2026

Company Update / Analyst / Investor Meet View filing →
31 July 2026 · 19:19 IST

Investor Presentation

Investor Presentation

Investor Presentation - Q1 FY 26-27

Company Update / Investor Presentation View filing →
31 July 2026 · 19:12 IST

Press Release

Press Release / Media Release

Please find attached Press Release and Management Discussion & Analysis for the first quarter ended June 30, 2026

Company Update / Press Release / Media Release View filing →
31 July 2026 · 19:01 IST

General

Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - List Of Officials

Please find attached Company's officials authorised for the purpose of determining materiality of an event or information and making disclosures to the Stock Exchanges

Company Update / General View filing →
31 July 2026 · 18:52 IST

Record Date

Intimation Of Record Date For Dividend

Intimation of Record Date for Dividend

Corp. Action / Record Date View filing →
31 July 2026 · 18:38 IST

Board Outcome

Board Meeting Outcome for Board Meeting Outcome - Unaudited Standalone And Consolidated Financial Results For The Quarter Ended June 30, 2026

The Board of Directors has considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026

Board Meeting / Outcome of Board Meeting View filing →
28 July 2026 · 22:39 IST

Press Release

Press Release / Media Release

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Company Update / Press Release / Media Release View filing →
21 July 2026 · 15:20 IST

Analyst / Investor Meet

Analyst / Investor Meet - Intimation

Intimation of Earnings Call

Company Update / Analyst / Investor Meet View filing →
21 July 2026 · 08:43 IST

Press Release

Press Release / Media Release

Glenmark receives U.S. FDA approval to expand the use of RYALTRIS Nasal Spray for Children aged 6 to less than 12 years

Company Update / Press Release / Media Release View filing →

RSS feed for Glenmark Pharmaceuticals Ltd · the 50 most recent filings

Price
Market cap
Sector
Index
PE
Latest quarter revenue
Net profit
Filings in the window